Title: ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
Journal: Translational research : the journal of laboratory and clinical medicine 20160901
Title: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20150901
Title: Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Journal: Oncotarget 20150821
Title: Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Journal: Hematological oncology 20150601
Title: Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Journal: Cancer science 20150301
Title: In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Journal: Molecular pharmacology 20150101
Title: Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Journal: Molecular cancer therapeutics 20140501
Title: Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.
Journal: Journal of medicinal chemistry 20140327
Title: Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20140315
Title: Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Journal: Scientific reports 20140101
Title: The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Journal: Molecular cancer therapeutics 20131001
Title: Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Journal: Leukemia 20130901
Title: Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Journal: British journal of haematology 20130801
Title: A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
Journal: PloS one 20130101
Title: Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.
Journal: American journal of cancer research 20130101
Title: Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.
Journal: PloS one 20130101
Title: Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Journal: Laboratory investigation; a journal of technical methods and pathology 20121001
Title: Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Journal: Leukemia research 20120801
Title: Targeting cyclin D1 for high risk myelodysplastic syndromes.
Journal: Leukemia research 20120801
Title: Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Journal: Leukemia research 20120101
Title: Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
Journal: Journal of pharmaceutical and biomedical analysis 20111215
Title: Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Journal: Seminars in oncology 20111001
Title: Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.
Journal: Journal of medicinal chemistry 20110922
Title: Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.
Journal: Cancer research 20110715
Title: Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100901
Title: A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Journal: Molecular cancer therapeutics 20100201
Title: Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Journal: Cancer chemotherapy and pharmacology 20091201
Title: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Journal: The oncologist 20090601
Title: Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Journal: Oncogene 20090326
Title: Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Journal: Oncogene 20090129
Title: Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201
Title: Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901
Title: Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Journal: IUBMB life 20051001
Title: Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.
Title: Hyoda T, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015 Mar;106(3):287-93.
Title: Gumireddy K, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005 Mar;7(3):275-86.
Title: Reddy MV, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methylphenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem.
Title: Chapman CM, et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18(7):1979-91
